Biogen (NASDAQ:BIIB) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Biogen from a "Hold" to a "Buy".
• Biogen beat Q1 expectations with $3.57 EPS and $2.48B revenue and set FY2026 guidance of 14.25–15.25 EPS, yet analyst views remain mixed and the MarketBeat consensus is still "Hold" with an average price target of $214.23.
• The Apellis transaction will create a ~$120–$130M other‑income headwind in 2026 (with non‑GAAP EPS accretion expected in 2027), a near‑term earnings drag that has pressured sentiment despite positive pipeline and sales momentum.

Biogen (NASDAQ:BIIB - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

BIIB has been the subject of a number of other reports. Truist Financial reduced their target price on shares of Biogen from $193.00 to $189.00 and set a "hold" rating for the company in a research note on Monday, April 13th. Sanford C. Bernstein reduced their target price on shares of Biogen from $201.00 to $200.00 in a research note on Thursday. Wolfe Research set a $231.00 target price on shares of Biogen in a research note on Monday, February 9th. Citigroup lifted their target price on shares of Biogen from $190.00 to $200.00 and gave the company a "neutral" rating in a research note on Friday. Finally, Wells Fargo & Company lifted their target price on shares of Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research note on Sunday, February 8th. Thirteen research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $214.23.

Biogen Price Performance

NASDAQ BIIB opened at $187.06 on Friday. The company has a quick ratio of 2.03, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $27.62 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.55 and a beta of 0.19. The company has a 50 day moving average price of $184.52 and a two-hundred day moving average price of $176.06. Biogen has a 12-month low of $115.25 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts' expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts predict that Biogen will post 15.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.18% of the company's stock.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company's stock worth $3,070,514,000 after buying an additional 157,857 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company's stock worth $736,435,000 after buying an additional 130,618 shares during the last quarter. Norges Bank acquired a new stake in shares of Biogen in the fourth quarter worth $464,408,000. Invesco Ltd. lifted its stake in shares of Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company's stock worth $338,731,000 after buying an additional 98,001 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Biogen by 3.3% in the fourth quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company's stock worth $409,180,000 after buying an additional 73,478 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.